WADE WYCKOFF
Prescription History 1689243149
Physical Medicine & Rehabilitation in Shreveport, LA

NPI Status: Active since June 20, 2021

Contact Information

1111 LINE AVE
SHREVEPORT, LA
ZIP 71101
Phone: (318) 716-4545

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for WADE WYCKOFF, an active Physical Medicine & Rehabilitation specialist practicing in Shreveport, LA. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 29 documented patient claims. Among these therapy options, the most frequently utilized medication is Atorvastatin Calcium, which accounts for 15 claims alone.

Medication Index

No matching medications currently found on file.

Atorvastatin Calcium

Generic Formulation: Atorvastatin CalciumSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 15
30-Day Fills 19.0
Days Supply 570
LA State Average Benchmarks
Peer Average Claims190.0
Peer Average 30-Day Fills437.5
Peer Average Days Supply12,998
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 92.1% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $118.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.91

State Avg Cost Per Claim

$10.83

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrole and heptanoic acid derivative, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR (statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL; APOLIPOPROTEIN B; and TRIGLYCERIDES. It is used to increase serum levels of HDL-CHOLESTEROL in the treatment of HYPERLIPIDEMIAS, and for the prevention of CARDIOVASCULAR DISEASES in patients with multiple risk factors.

Therapeutic Applications

Atorvastatin is used along with a proper diet to help lower bad cholesterol and fats (such as LDL, triglycerides) and raise good cholesterol (HDL) in the blood. It belongs to a group of drugs known as statins. It works by reducing the amount of cholesterol made by the liver. Lowering bad cholesterol and triglycerides and raising good cholesterol decreases the risk of heart disease and helps prevent strokes and heart attacks. In addition to eating a proper diet (such as a low-cholesterol/low-fat diet), other lifestyle changes that may help this medication work better include exercising, losing weight if overweight, and stopping smoking. Consult your doctor for more details.

Eliquis

Generic Formulation: ApixabanSpecialty: Student in an Organized Health Care Education/Training Program
Provider Metrics Summary
Total Claims 14
30-Day Fills 14.0
Days Supply 338
LA State Average Benchmarks
Peer Average Claims97.0
Peer Average 30-Day Fills135.5
Peer Average Days Supply3,768
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 85.6% less volume than the regional standard for practitioners inside LA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,363.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$454.55

State Avg Cost Per Claim

$714.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like WADE WYCKOFF provides transparency into local medical care patterns within Shreveport, LA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Physical Medicine & Rehabilitation** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.